Welcome to our dedicated page for Rocket Pharmaceu SEC filings (Ticker: RCKT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rocket Pharmaceuticals, Inc. filings document regulatory, financial, governance, and capital-structure disclosures for a biotechnology company developing and commercializing genetic therapies for rare disorders. Recent 8-K reports cover quarterly and annual operating results, FDA-related events for KRESLADI, Priority Review Voucher monetization, and clinical-program updates for cardiovascular gene therapy candidates.
The filing record also includes definitive proxy materials for annual-meeting governance matters and material-agreement disclosures related to an at-the-market common stock offering program under a shelf registration statement. These documents describe board and shareholder-vote matters, equity financing mechanics, common stock structure, business risks, and formal disclosure controls around product approvals and development programs.
ROCKET PHARMACEUTICALS, INC. CEO Gaurav Shah sold 12,279 shares of common stock at $3.312 per share on February 13, 2026 in an open-market transaction. According to the footnotes, the sale was made to cover tax withholding obligations tied to vesting restricted stock units that convert one-for-one into common shares. After this sale, Shah directly holds 1,052,045 shares, and also reports indirect holdings of 207,897 shares held by his spouse and 198,341 shares held by the Gaurav D. Shah Irrevocable Trust.
Rocket Companies insider sale notice: a Form 144 lists 1,157 common shares related to restricted stock vesting dated 02/13/2026.
The filing also records prior sales by John Militello: 1,086 shares on 11/18/2025 and 3,726 shares on 02/13/2026.
RCKT filing of a Form 144 reports proposed sale of 1,376 common shares tied to restricted stock vesting dated 02/13/2026. The filing also records prior sales by the reporting person: 1,646 shares on 11/18/2025 and 12,253 shares on 02/13/2026.
Issuer reported Form 144 sale notice for restricted shares by an affiliate. The filing lists 5,990 common shares offered for sale related to a restricted stock vesting event on 02/13/2026. It also shows prior transactions by Gaurav Shah: 6,276 shares sold on 11/18/2025 and 12,279 shares sold on 02/13/2026.
Rocket Pharmaceuticals insider Martin Wilson has filed a notice to sell 12,253 common shares. The shares were recently acquired through restricted stock vesting on 02/11/2026 as compensation from the issuer. The planned sale through Fidelity Brokerage Services LLC has an aggregate market value of $40,583.16 and is listed for trading on NASDAQ, with an approximate sale date of 02/13/2026. The filing notes that 108,222,228 common shares were outstanding, and also discloses a prior sale of 1,646 shares for $4,909.69 on 11/18/2025.
Maverick Capital and related entities filed an amended Schedule 13G reporting their beneficial ownership of Rocket Pharmaceuticals common stock. They report beneficial ownership of 2,513,110 shares of Rocket, representing 2.3% of the outstanding common stock, based on 108,222,228 shares outstanding as of October 31, 2025.
The shares are held for Maverick’s investment advisory clients, including Maverick HP, L.P. with 1,917,698 shares and certain separately managed accounts with 595,412 shares. The filers certify that the securities were not acquired to change or influence control of Rocket Pharmaceuticals.
Shah Gaurav reported acquisition or exercise transactions in a Form 4 filing for RCKT. The filing lists transactions totaling 1,156,676 shares. Following the reported transactions, holdings were 870,648 shares.
Rocket Pharmaceuticals officer John Militello received new equity awards. On February 11, 2026, he was granted 29,982 shares of common stock at a price of $0, increasing his directly held common stock to 95,902 shares.
He was also granted a stock option covering 45,018 shares at an exercise price of $3.24 per share. Both the restricted stock units and the option vest one-third on February 11, 2027, with the remaining portions vesting in equal quarterly installments over the following two years, subject to continued employment.
Rocket Pharmaceuticals General Counsel Martin Wilson received new equity awards. On February 11, 2026, he was granted 311,813 shares of common stock in the form of restricted stock units at a price of $0 per share, bringing his directly held common stock (including RSUs) to 695,629 shares.
He was also granted a stock option for 468,187 shares at an exercise price of $3.24 per share, expiring February 11, 2036. One-third of both the RSUs and the option will vest on February 11, 2027, with the remaining portions vesting in equal quarterly installments over the following two years, contingent on continued employment.
Rocket Pharmaceuticals’ Chief Medical Officer Syed Ali-aamir Rizvi received new equity awards. On February 11, 2026, he was granted 61,963 shares of common stock in the form of restricted stock units at $0 per share, bringing his directly held common stock (including RSUs) to 407,874 shares.
He was also granted a stock option covering 93,037 shares of common stock with an exercise price of $3.24 per share. For both the RSUs and the option, one-third vests on February 11, 2027, with the remainder vesting in equal quarterly installments over the following two years, contingent on continued employment.